Effects of finasteride and cyproterone acetate on hematuria associated with benign prostatic hyperplasia: A prospective, randomized, controlled study

Urology

Volumn 59, Issue 3, 2002, Pages 373-377

  Perimenis, Petros ^a,b   Gyftopoulos, Kostis ^a   Markou, Spyros ^a   Barbalias, George ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; CYPROTERONE ACETATE; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CATHETERIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOSCOPY; CYTOLOGY; DOUBLE BLIND PROCEDURE; ECHOGRAPHY; HEMATURIA; HUMAN; INTRAVENOUS UROGRAPHY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; STATISTICAL ANALYSIS; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; URINE CULTURE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; CYPROTERONE ACETATE; FINASTERIDE; HEMATURIA; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; RECURRENCE;

EID: 0036191105     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(01)01548-5     Document Type: Article

References (28)

1. Transurethral prostatectomy; immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients
2. Epsilon-aminocaproic acid (EACA)
3. Epsilon-aminocaproic acid and the control of post-prostatectomy bleeding; a prospective double blind study
4. The effects of finasteride on hematuria associated with benign prostatic hyperplasia; a preliminary report
5. Effects of finasteride on hematuria associated with benign prostatic hyperplasia; long-term follow-up
6. The treatment of gross hematuria secondary to prostatic bleeding with finasteride
7. A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride
8. Rapid diagnostic service for patients with haematuria
9. Same day diagnostic service for new cases of hematuria-a district general hospital experience
10. Treatment of prostatic bleeding; suppression of angiogenesis by androgen deprivation
11. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia
12. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia
13. Dihydrotestosterone and the concept of 5α-reductatse inhibition in human benign prostatic hyperplasia
14. Finasteride, an inhibitor of 5α-reductase suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia
15. Androgen metabolism in men receiving finasteride before prostatectomy
16. Effect of finasteride, a 5α-reductatse inhibitor on prostate tissue androgens and prostate-specific antigen
17. Cyproterone acetate-mechanism of action and clinical effectiveness in prostate cancer treatment
18. Treatment of benign prostatic hyperplasia by androgen deprivation; effects on prostate size and urodynamic parameters
19. Medical treatment of benign nodular prostatic hyperplasia with cyproterone acetate
20. Angiogenic activity as a marker of neoplastic and preneoplastic lesions of the human bladder
21. Role of finasteride in the treatment of recurrent hematuria secondary to benign prostatic hyperplasia
22. Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts
23. Microvessel density in prostatic hyperplasia
24. Effect of finasteride on microvessel density (MVD) in patients with recurrent hematuria related to prostatic hypertrophy (BPH)
25. Prostatic involution in rats induced by a novel 5α-reductase inhibitor, SK&F 105567; role for testosterone in the androgenic response
26. Evidence for atrophy and apoptosis in the prostates of men given finasteride
27. Comment to; The treatment of gross hematuria secondary with prostatic bleeding with finasteride
28. Antiandrogens as monotherapy for prostate cancer